Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% EV-to-OCF is 62.31 as of Jul. 28, 2026, which is 239% above its 10-year median of 18.39. The stock has 8 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Resonance Health ranks worse than 93.7% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Resonance Health's Enterprise Value is A$26.17 Mil.
Resonance Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.42 Mil. Therefore, Resonance Health's EV-to-OCF for today is 62.31.
The historical rank and industry rank for Resonance Health's EV-to-OCF or its related term are showing as below:
ASX:RHT'
s EV-to-OCF Range Over the Past 10 Years
Min: -204.28 Med: 18.39 Max: 209.45
Current: 62.31
During the past 13 years, the highest EV-to-OCF of Resonance Health was 209.45. The lowest was -204.28. And the median was 18.39.
ASX:RHT's EV-to-OCF is ranked worse than 93.7% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 8.7
vs ASX:RHT: 62.31
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Resonance Health's PE Ratio (TTM) for today is calculated as:
Resonance Health's share price for today is A$0.056.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Resonance Health EV-to-OCF Related Terms
Resonance Health EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Resonance Health's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Resonance Health's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Resonance Health's EV-to-OCF falls into.
Resonance Health's current Enterprise Value is A$26.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a EV-to-OCF of 62.31 as of Jul. 28, 2026. This is 239% above median its historical median of 18.39. According to the industry distribution chart, Resonance Health ranks #640 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 93.7%.
Is Resonance Health's EV-to-OCF too high?
Resonance Health's current EV-to-OCF of 62.31 is 239% above median its 10-year median of 18.39. The Healthcare Providers & Services industry median EV-to-OCF is 8.70. Resonance Health's value of 62.31 is 616.2% above this industry median. Based on the distribution chart, Resonance Health ranks #640 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Resonance Health's EV-to-OCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #640 out of 683 companies for EV-to-OCF. This places Resonance Health in the lower half of its industry. The industry median EV-to-OCF is 8.70. Resonance Health's value of 62.31 is 616.2% above this benchmark. While the company's 10-year median is 18.39 vs. the industry median of 8.70, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.70, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current EV-to-OCF of 62.31 is 616.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current EV-to-OCF is 62.31, which is 239% above median its own 10-year median of 18.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current EV-to-OCF is 62.31, which is 239% above median its 10-year median of 18.39 and 616.2% above the Healthcare Providers & Services industry median of 8.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current EV-to-OCF is 62.31 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
